BrainsWay (BrainsWay) Institutional Ownership : 4.80% (As of May. 26, 2024)

View and export this data going back to 2012. Start your Free Trial

What is BrainsWay Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, BrainsWay's institutional ownership is 4.80%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, BrainsWay's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, BrainsWay's Float Percentage Of Total Shares Outstanding is 68.85%.

BrainsWay Institutional Ownership Historical Data

The historical data trend for BrainsWay's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BrainsWay Institutional Ownership Chart

BrainsWay Historical Data

The historical data trend for BrainsWay can be seen below:

	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-02-29	2024-03-31	2024-04-30
Institutional Ownership	3.32	3.62	4.34	4.42	4.58	4.34	3.94	4.77	4.80	4.80

BrainsWay Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

BrainsWay (BrainsWay) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BrainsWay Ltd (OTCPK:BRSYF) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

BWAY:USA BWAY:Israel

Address

19 Hartum Street, 3rd Floor, Bynet Building, Har Hotzvim, Jerusalem, ISR, 9777518

Website

https://www.brainsway.com

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.